Sign inJoin waitlistJoin the waitlist

Carlos Zarate

Chief, Experimental Therapeutics and · Clinical Center at the National Institutes of Health

Credentials: · ·

History

Experimental Therapeutics and Division · Clinical Center at the National Institutes of Health
Present
George Washington University School of Medicine
Present

McLean Hospital
1989–1990
McLean Hospital
1986–1989
Universidad Católica de Córdoba Facultad de Medicina
1982–1986

Research

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
Archives of General Psychiatry · 2006 · First of 8 authors · Corresponding · 2,826 citations
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Nature · 2016 · 1,297 citations
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors
Biological Psychiatry · 2008 · 958 citations

MT
Mauricio Tohen
52 papers
Mark Niciu
47 papers · 21 as a fellow
BK
Bashkim Kadriu
39 papers
WD
Wayne Drevets
36 papers
Erica Richards
34 papers · 19 as a resident
DI
Dawn Ionescu
28 papers · 8 as a resident
LI
Lobna Ibrahim
18 papers
ND
Nancy Diazgranados
18 papers · 13 as a resident
Mani Yavi
17 papers · 1 as a resident
Dennis Charney
16 papers
DM
Daniel Mathews
15 papers
Jair Soares
15 papers

Grants

Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect
National Institute of Mental Health · ZIA
Contact PI · $54.4M · National Institute of Mental Health
Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders
National Institute of Mental Health · ZIA
Contact PI · $37.1M · National Institute of Mental Health
Non-Invasive Neuromodulation Unit (NNU)
National Institute of Mental Health · ZIA
Contact PI · $6.4M · National Institute of Mental Health
Cholinergic Modulation of Cognition and Emotion in Mood Disorders
National Institute of Mental Health · ZIA
Contact PI · $2.9M · National Institute of Mental Health

Clinical trials

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Principal investigator · Recruiting · Phase 2
National Institute of Mental Health (NIMH)
2024–2027
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
Principal investigator · Terminated · Phase 2
National Institute of Mental Health (NIMH)
2021–2024
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Principal investigator · Recruiting · Phase 1
National Institute of Mental Health (NIMH)
2020–2027
Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes
Principal investigator · Completed
National Institute of Mental Health (NIMH)
2018–2025